Baseline Cytogenetic Testing Performed on Bone Marrow

PQRI Data Collection Sheet

| | | | / / | 🗆 Male 🛛 Female |
|--|--------------------------------------|----|--|--|
| Patient's Name Practice Medical Record Nur | Practice Medical Record Number (MRN) | | Birth Date (mm/dd/yyyy) | Gender |
| National Provider Identifier (NPI) | | | Date of Service | |
| Clinical Information | | | Billing Information | |
| Step 1 Is patient eligible for this measure? | | | | |
| | Yes | No | Code Required on Claim Form | |
| Patient is aged 18 years and older on date of encounter. | | | Verify date of birth on claim for | orm. |
| Patient has a line item diagnosis of myelodysplastic syndrome or an acute leukemia. | | | Refer to coding specifications document for list of applicable codes. Codes determining a patient's eligibility must be reported on the same claim as the quality code(s) identified below. | |
| There is a CPT E/M Service Code for this visit. | | | | |
| If No is checked for any of the above, STOP. Do not report a CPT category II code. | | | | |
| Step 2 Does patient meet or have an acceptable reason for not meeting the measure? | | | | |
| Baseline Cytogenetic Testing ¹ on Bone Marrow | Yes | No | Code to be Reported on Line 24 if <i>Yes</i> (or Service Line 24 of Eld | |
| Performed | | | 3155F | |
| Not performed for one of the following reasons: • Medical (eg, no liquid bone marrow or fibrotic marrow) | | | 3155F–1P | |
| Patient (eg, at time of diagnosis receiving palliative care or not receiving treatment as defined above) | | | 3155F-2P | |
| System (eg, patient previously treated by another physician at the time cytogenetic testing performed) | | | 3155F–3P | |
| Document reason here and in medical chart. | | | If No is checked for all of the all 3155F–8P (Cytogenetic testing not perfor at time of diagnosis or prior to reason not otherwise specified | rmed on bone marrow initiating treatment, |

¹Baseline cytogenetic testing refers to testing that is performed at time of diagnosis or prior to initiating treatment (transfusion, growth factors, or antineoplastic therapy) for that diagnosis.

PQRI 2009 Measure 67, Effective Date 01/01/2009 © 2006–7 American Medical Association and American Society of Hematology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. (Disclaimers, Copyright and other Notices indicated on the Coding Specifications document are incorporated by reference) CPT® copyright 2008 American Medical Association